{
    "id": "f8bb1621-325d-4e78-a34e-ff226f759e6f",
    "indications": {
        "text": "skytrofa ( lonapegsomatropin-tcgd ) human growth hormone indicated treatment pediatric patients 1 year older weigh least 11.5 kg growth failure due inadequate secretion endogenous growth hormone ( gh ) .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "skytrofa administered subcutaneously abdomen , buttock , thigh regular rotation injection sites ( 2.5 ) . recommended dose 0.24 mg/kg body weight once-weekly . full prescribing information instructions preparation ( 2.4 , 2.5 ) .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "skytrofa ( lonapegsomatropin-tcgd ) injection sterile , preservative-free , white off-white lyophilized powder available single-dose , dual-chamber , prefilled cartridge containing lonapegsomatropin-tcgd one chamber diluent , water injection , second chamber . dual-chamber glass cartridge available 9 strengths ( somatropin equivalents ) described table 6. table 6 : skytrofa presentations skytrofa ndc 3 mg 73362-003-01 3.6 mg 73362-004-01 4.3 mg 73362-005-01 5.2 mg 73362-006-01 6.3 mg 73362-007-01 7.6 mg 73362-008-01 9.1 mg 73362-009-01 11 mg 73362-010-01 13.3 mg 73362-011-01 carton contains 4 single-dose prefilled cartridges 6 sterile , single-use , disposable 0.25 mm \u00d7 4 mm ( 31-gauge \u00d7 5/32 inch ) needles . cartridges skytrofa auto-injector , packaged separate carton . skytrofa auto-injector supplied skytrofa cartridges available patients prescription skytrofa ascendis pharma customer support calling toll-free number 1-844-442-7236 ( 1-844-44ascendis ) .",
    "adverseReactions": "skytrofa contraindicated patients : acute critical illness open heart surgery , abdominal surgery multiple accidental trauma , acute respiratory failure due risk increased mortality pharmacologic doses somatropin [ ( 5.1 ) ] . hypersensitivity somatropin excipients skytrofa . severe systemic hypersensitivity , including anaphylactic angioedema , reported [ ( 5.2 ) ] . closed epiphyses . active malignancy due risk malignancy progression [ ( 5.3 ) ] . active proliferative severe non-proliferative diabetic retinopathy treatment somatropin may worsen condition . prader-willi syndrome severely obese , history upper airway obstruction sleep apnea severe respiratory impairment due risk sudden death [ ( 5.13 ) ] .",
    "ingredients": [
        {
            "name": "Lonapegsomatropin",
            "code": "OP35X9610Y",
            "drugbank_id": "https://go.drugbank.com/drugs/DB16220"
        }
    ],
    "organization": "Ascendis Pharma Endocrinology, Inc.",
    "name": "Skytrofa",
    "effectiveTime": "20250506",
    "indications_original": "SKYTROFA (lonapegsomatropin-tcgd) is a human growth hormone indicated for the treatment of pediatric patients 1 year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous growth hormone (GH).",
    "contraindications_original": "SKYTROFA should be administered subcutaneously into the abdomen, buttock, or thigh with regular rotation of the injection sites ( 2.5 ). The recommended dose is 0.24 mg/kg body weight once-weekly. See Full Prescribing Information for instructions on preparation and administration of drug ( 2.4 , 2.5 ).",
    "warningsAndPrecautions_original": "SKYTROFA (lonapegsomatropin-tcgd) for injection is a sterile, preservative-free, white to off-white lyophilized powder available in a single-dose, dual-chamber, prefilled cartridge containing lonapegsomatropin-tcgd in one chamber and the diluent, Water for Injection, in the second chamber. The dual-chamber glass cartridge is available in 9 strengths (in somatropin equivalents) as described in Table 6.\n                        \n                           Table 6:\tSKYTROFA Presentations\n                           \n                           \n                           \n                              \n                                 SKYTROFA\n                                 NDC\n                              \n                           \n                           \n                              \n                                 3 mg\n                                 73362-003-01\n                              \n                              \n                                 3.6 mg\n                                 73362-004-01\n                              \n                              \n                                 4.3 mg\n                                 73362-005-01\n                              \n                              \n                                 5.2 mg\n                                 73362-006-01\n                              \n                              \n                                 6.3 mg\n                                 73362-007-01\n                              \n                              \n                                 7.6 mg\n                                 73362-008-01\n                              \n                              \n                                 9.1 mg\n                                 73362-009-01\n                              \n                              \n                                 11 mg\n                                 73362-010-01\n                              \n                              \n                                 13.3 mg\n                                 73362-011-01\n                              \n                           \n                        \n                        Each carton contains 4 single-dose prefilled cartridges and 6 sterile, single-use, disposable 0.25 mm \u00d7 4 mm (31-gauge \u00d7 5/32 inch) needles. The cartridges are for use only with the SKYTROFA Auto-Injector, packaged in a separate carton. The SKYTROFA Auto-Injector is not supplied with SKYTROFA cartridges but is available for patients with a prescription for SKYTROFA through the Ascendis Pharma Customer Support by calling the toll-free number at 1-844-442-7236 (1-844-44ASCENDIS).",
    "adverseReactions_original": "SKYTROFA is contraindicated in patients with:\n                  \n                  \n                     Acute critical illness after open heart surgery, abdominal surgery or multiple accidental trauma, or those with acute respiratory failure due to the risk of increased mortality with use of pharmacologic doses of somatropin [see Warnings and Precautions (5.1)].\n                     Hypersensitivity to somatropin or any of the excipients in SKYTROFA. Severe systemic hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported [see Warnings and Precautions (5.2)].\n                     \n                     Closed epiphyses.\n                     Active malignancy due to the risk of malignancy progression [see Warnings and Precautions (5.3)].\n                     \n                     Active proliferative or severe non-proliferative diabetic retinopathy because treatment with somatropin may worsen this condition.\n                     Prader-Willi syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea or have severe respiratory impairment due to the risk of sudden death [see Warnings and Precautions (5.13)].",
    "drug": [
        {
            "name": "Skytrofa",
            "drugbank_id": "https://go.drugbank.com/drugs/DB16220"
        }
    ]
}